Article
Multidisciplinary Sciences
Hyung Jin Hahn, Sang Gyu Kwak, Dong-Kyu Kim, Jong-Yeup Kim
Summary: Research indicates that individuals with Behcet disease are more likely to develop psoriasis, with higher risk seen in male BD patients and older individuals. Additionally, Behcet disease patients are also more prone to developing psoriatic arthritis.
SCIENTIFIC REPORTS
(2021)
Article
Rheumatology
William Tillett, Alexis Ogdie, Alun Passey, Patricia Gorecki
Summary: This study aimed to assess baseline differences between plaque psoriasis alone and concomitant PsA patients and to investigate the impact of these characteristics on ustekinumab (UST) persistence and outcomes. Results showed that patients with concomitant PsA had a greater comorbidity burden, including hypertension, diabetes, obesity, and depression, and a greater inability to work. PsA, female sex, and depression were associated with shorter UST persistence. These findings emphasize the need for patient-centric, multidisciplinary care in screening for and managing comorbidities in psoriasis and PsA treatment.
Review
Medicine, General & Internal
Fei Qi, Yaqi Tan, Amin Yao, Xutong Yang, Yanling He
Summary: Psoriatic disease is a spectrum of diseases affecting both skin and musculoskeletal features, with a considerable number of patients progressing from cutaneous psoriasis to psoriatic arthritis. The use of proteomics technologies provides a unique opportunity to explore potential biomarkers for psoriatic arthritis.
FRONTIERS IN MEDICINE
(2021)
Article
Immunology
Guillaume Larid, Adriana Delwail, Thomas Dalle, Philippe Vasseur, Christine Silvain, Jean-Francois Jegou, Franck Morel, Jean-Claude Lecron, Elisabeth Gervais
Summary: Psoriatic arthritis (PsA) and cutaneous psoriasis (PsO) exhibit distinct cytokine production profiles, which are influenced by clinical phenotype and metabolic syndrome.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Weize Gao, Zhan Wang, Wenshuai Li, Yongxin Li, Mingjun Liu
Summary: This review systematically demonstrates the research progress of psoriasis-related biomarkers and elaborates their related mechanisms in the pathological development of psoriasis and psoriatic arthritis. In addition, we summarize the development of biologic therapies for psoriasis and psoriatic arthritis in order to drive the broader discussion of psoriasis as an autoimmune-mediated inflammatory skin disease.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Piero Ruscitti, Maria Esposito, Ilenia Di Cola, Cristina Pellegrini, Andrea De Berardinis, Mirco Mastrangelo, Camilla Gianneramo, Antonio Barile, Maria Concetta Fargnoli, Paola Cipriani
Summary: This study aimed to evaluate biomolecules in naive patients with psoriasis (PSO), psoriatic arthritis (PSA) with PSO, and PSA sine PSO. The results showed that these patients have a similar cytokine profile, suggesting the concept of a psoriatic disease continuum. However, differences were also found, indicating possible pathogenic differences and contributing to the clinical heterogeneity of these patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Jean-Guillaume Letarouilly, Benoit Flachaire, Celine Labadie, Maeva Kyheng, Nicolas Cohen, Jeremie Sellam, Pascal Richette, Philippe Dieude, Pascal Claudepierre, Bruno Fautrel, Eric Houvenagel, Chi Duc Nguyen, Marie-Helene Guyot, Nicolas Segaud, Laurent Marguerie, Xavier Deprez, Jean-Hugues Salmon, Guy Baudens, Corinne Miceli-Richard, Elisabeth Gervais, Isabelle Chary-Valckenaere, Pierre Lafforgue, Peggy Philippe, Damien Loeuille, Christophe Richez, Florence Tubach, Thao Pham, Rene-Marc Flipo
Summary: This study evaluated the real-world persistence of ustekinumab (UST) and secukinumab (SEK) in patients with Psoriatic Arthritis (PsA) and found that SEK had a higher persistence rate compared to UST, especially when used in combination with MTX. Discontinuation due to inefficacy was the most common reason for discontinuation in both UST and SEK groups.
Article
Rheumatology
Philip J. Mease, Mei Liu, Sabrina Rebello, Robert R. McLean, Blessing Dube, Meghan Glynn, Peter Hur, Alexis Ogdie
Summary: Patients with PsA who have nail psoriasis demonstrated worse disease activity, quality of life, and work productivity compared to those without nail involvement, highlighting the importance of identifying and managing nail disease in PsA patients.
JOURNAL OF RHEUMATOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Irmina Olejniczak-Staruch, Magdalena Ciazynska, Dorota Sobolewska-Sztychny, Joanna Narbutt, Malgorzata Skibinska, Aleksandra Lesiak
Summary: Numerous scientific studies have shown significant skin and gut dysbiosis in patients with psoriasis, with changes in abundance of specific bacterial taxa. Treatments for psoriasis have been found to significantly influence skin and gut microbiome, with orally administered probiotics having a positive impact on the course of the disease. Further research is needed to understand the influence of microbiome on the development of inflammatory skin diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Public, Environmental & Occupational Health
Holly R. Harris, Karen Moreno Nascimento Korkes, Tricia Li, Marina Kvaskoff, Eunyoung Cho, Luiz Fernando Carvalho, Abrar A. Qureshi, Mauricio Abrao, Stacey A. Missmer
Summary: A bidirectional association between endometriosis and psoriasis with PsA was found in this study. Psoriasis with concomitant PsA was associated with a higher risk of laparoscopically confirmed endometriosis, while the diagnosis of endometriosis was suggestive of subsequent risk of psoriasis with PsA.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2022)
Article
Rheumatology
Ran Cui, Hua Zhang, Miao Chen, Qian Wang, Qiang Tong, Zhiyong Chen, Ke-Xiang Yan, Yang-Feng Ding, Sheng-Ming Dai
Summary: Nail disease is associated with psoriatic arthritis (PsA), and onycholysis and hyperkeratosis are independently associated with PsA. Onycholysis has higher accuracy and sensitivity for diagnosing PsA compared to pitting and hyperkeratosis.
CLINICAL RHEUMATOLOGY
(2022)
Article
Rheumatology
Judith Haschka, David Simon, Sara Bayat, Zora Messner, Eleni Kampylafka, Filippo Fagni, Susanna Skalicky, Matthias Hackl, Heinrich Resch, Jochen Zwerina, Arnd Kleyer, Alexander Cavallaro, Michael Sticherling, Goerg Schett, Roland Kocijan, Juergen Rech
Summary: This study aimed to identify circulating miRNA signatures associated with psoriasis (PsO) and psoriatic arthritis (PsA) patients. The results show significant differences in miRNA signatures between PsA and PsO patients compared to controls, with five miRNAs being involved in bone and cartilage metabolism, suggesting a link between psoriatic inflammation and bone/cartilage changes.
Review
Medicine, General & Internal
Mihaela Agache, Claudiu C. Popescu, Luminita Enache, Bianca M. Dumitrescu, Catalin Codreanu
Summary: Ultrasonography is advantageous for assessing psoriatic arthritis (PsA) due to its ability to evaluate multiple targets, including joints, entheses, and tendons, as well as skin and nails. However, the use of nail ultrasound in medical practice is limited due to the requirement for probes with a higher frequency. This article narratively evaluates recent studies on the value of nail ultrasound in diagnosing and monitoring PsA.
Article
Rheumatology
Timothy S. H. Kwok, Mitchell Sutton, Daniel Pereira, Richard J. Cook, Vinod Chandran, Nigil Haroon, Robert D. Inman, Dafna D. Gladman
Summary: Isolated axial PsA and AS with psoriasis are relatively uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may predict the development of peripheral disease. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Medicine, General & Internal
Stephen R. Pennington, Oliver FitzGerald
Summary: Although having skin/nail psoriasis is an important risk factor for developing psoriatic arthritis (PsA), it alone is not sufficient to identify which patients with psoriasis will develop PsA. Further molecular assessment of psoriasis patients may help refine the profile of those at risk of developing PsA, leading to the design of disease prevention studies and new treatment approaches.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
Oras A. Alabas, Kayleigh J. Mason, Zenas Z. N. Yiu, Philip J. Hampton, Nick J. Reynolds, Caroline M. Owen, Anthony Bewley, Philip M. Laws, Richard B. Warren, Mark Lunt, Catherine H. Smith, Christopher E. M. Griffiths, BADBIR Study Grp
Summary: This study found that the real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters, and methotrexate were generally low for patients with moderate-to-severe psoriasis. Risk factors associated with treatment ineffectiveness included prior nonbiologic systemic therapies, male sex, comorbidities, and alcohol consumption.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Richard G. Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard B. Warren, Carle Paul, Jacek C. Szepietowski, Tsen-Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Summary: The 5-year treatment study demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque psoriasis and improved their quality of life. The most common adverse events were infections and upper respiratory tract infections. The safety profile of secukinumab was consistent with previous clinical development program.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Georgios Kokolakis, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda Gooderham, Andreas Koerber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Summary: This study evaluated the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab, and secukinumab. The results showed rapid and durable improvements in clinical responses among nonresponders who switched to bimekizumab. Furthermore, the majority of patients who responded well to previous treatments maintained or improved their response after switching to bimekizumab. Overall, switching to bimekizumab was found to be highly effective and well tolerated for psoriasis patients.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Dermatology
Georgia Lada, Hector Chinoy, Peter S. Talbot, Richard B. Warren, C. Elise Kleyn
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Dermatology
Duc Binh Phan, Anthony P. Bewley, Catherine H. Smith, Teena Mackenzie, Christopher E. M. Griffiths, Mark Lunt, Richard B. Warren, Zenas Z. N. Yiu
Summary: This study investigated the uptake of TNFi biosimilars in the UK and Ireland and found that the use of biosimilars increased over time and varied across regions. Biosimilars were more commonly used by men and patients with lower disease severity.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Richard B. Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E. M. Griffiths, Jihao Zhou, Bruce Randazzo, Paul Lizzul, Johann E. Gudjonsson
Summary: In this study, the efficacy and safety of the anti-IL-36 receptor antibody imsidolimab in patients with generalized pustular psoriasis (GPP) were evaluated. Rapid and sustained improvement in symptoms and pustular eruptions of GPP were observed after imsidolimab treatment. These findings support imsidolimab as a therapeutic option for GPP.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Oras A. Alabas, Kayleigh J. Mason, Zenas Z. N. Yiu, Richard B. Warren, Mark Lunt, Catherine H. Smith, Christopher E. M. Griffiths, BADBIR Study Grp
Summary: The aim of this study was to determine the real-world effectiveness and survival of methotrexate (MTX) and adalimumab (ADA) in patients with moderate-to-severe psoriasis registered in BADBIR. The study found that patients on ADA were twice as likely to be clear or nearly clear of psoriasis and were less likely to discontinue their medication than patients on MTX.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G. Langley, Richard B. Warren, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul
Summary: It is important to evaluate the long-term efficacy of new treatments for psoriasis. This study found that the majority of patients who responded to bimekizumab treatment at Week 16 maintained a high level of clinical response after 3 years of treatment. These findings demonstrate the long-term effectiveness of bimekizumab in patients with moderate-to-severe plaque psoriasis and its important benefits for health-related quality of life.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Sarah Elyoussfi, Shraddha S. Rane, Steve Eyre, Richard B. Warren
Summary: Tyrosine kinase 2 (TYK2) plays an important role in the pathogenesis of psoriasis, and genome-wide association studies (GWAS) have identified TYK2 as a potential therapeutic target. Recent clinical trials have shown that TYK2 inhibitors have promise in treating psoriasis. Pathway analysis through genetic and genomic means is believed to be crucial for optimizing TYK2 therapy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2023)
Article
Dermatology
Richard B. Warren, Victoria Basey, Anita Lynam, Charlotte Curtis, Michael R. Ardern-Jones
Summary: A UK study found that people with atopic dermatitis (AD) have a 30% higher risk of deep-vein thrombosis and a 17% higher risk of venous thromboembolism (VTE). The increased VTE risk is lower in younger individuals and those without obesity. Identifying AD patients at higher VTE risk could impact clinical decision-making.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
April W. Armstrong, Richard B. Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniela Junqueira, Tracy Westley, Renata Kisa, Carolin Daamen, Matthias Augustin
Summary: Deucravacitinib, a newly approved oral medication for moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and placebo. A systematic review and network meta-analysis compared deucravacitinib with other systemic treatments, showing its high PASI 75 response rates that are comparable to first-generation biologics adalimumab and ustekinumab.
DERMATOLOGY AND THERAPY
(2023)
Meeting Abstract
Dermatology
S. Mahil, N. Dand, K. Bechman, E. Cook, T. Tsakok, Z. Yiu, S. Langan, H. McAteer, J. Galloway, K. Mason, R. Warren, F. Capon, P. DiMeglio, F. Meynell, B. Coker, A. Vincent, J. Kelly, D. Urmston, A. Vesty, C. Lancelot, H. Bachelez, C. Contreras, C. de la Cruz, P. Gisondi, D. Jullien, J. Lambert, L. Naldi, S. Norton, L. Puig, P. Spuls, T. Torres, H. Waweru, L. Moorhead, M. Yates, J. Weinman, M. Brown, C. Griffiths, J. Barker, C. Smith
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
A. Pinter, B. Strober, D. Rosmarin, P. Gisondi, V. Vanvoorden, L. Peterson, C. Madden, D. de Cuyper, R. Warren
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
S. Rane, S. Eyre, R. Warren
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
A. Al-Janabi, Z. Littlewood, C. Griffiths, H. Hunter, H. Chinoy, C. Moriarty, Z. Yiu, J. Limdi, R. Warren
BRITISH JOURNAL OF DERMATOLOGY
(2022)
